We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Ipsen Fails Again to Get its Tumor Drug Reclassified as a Biologic
Ipsen Fails Again to Get its Tumor Drug Reclassified as a Biologic
Despite another attempt by Ipsen Biopharmaceuticals to regain market exclusivity for its injectable neuroendocrine tumor drug Somatuline Depot (lanreotide), an appeals court has ruled once more in favor of the FDA.